A Combination of Teclistamab and Daratumumab Prolongs PFS in Patients with Relapsed or Refractory Multiple Myeloma By Ogkologos - January 12, 2026 440 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the MajesTEC-3 study Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR Breast Cancer Survivor And Teenage Son Hand-Sew Neck Pillows To Bring... August 15, 2019 Cleveland Clinic Launches Breast Cancer Vaccine Trial October 28, 2021 Obesity May Help Tumors Survive and Grow, Mouse Study Suggests January 22, 2021 No Additional Benefit From Tiragolumab Plus Atezolizumab Over Durvalumab in Locally... August 24, 2026 Load more HOT NEWS New Study Says At-Home Cancer Care May Lead to Fewer Hospitalizations... KRASG12 Mutations Are Biomarkers for Reduced Overall Survival Benefit of Treatment... FDA Approves Selumetinib for Paediatric Patients 1 Year of Age and... Six Years of Adjuvant Imatinib Improves DFS Over Three Years Treatment...
